On 2/21/19 Outlook Therapeutics filed for a $57 million offering in part to support its treatment for wet AMD (age related macular degeneration). The filing did not specify the number of shares to be offered.
Outlook is enrolling patients in a Ph III trial in Australia of ONS-510. ONS-510 is a proprietary formulation of bevacizumab administered as an intravitreal injection for the treatment of wet AMD and other retina diseases. The treatment is a monoclonal antibody that inhibits VEGF and associated angiogenic behavior.
The company closed separate rounds of private financing in January and early February of this year of $20 million each. The company changed its name from “Oncobiologics” to Outlook Therapeutics in December of 2018.
